CHARTWELL MOLECULAR
GenericsCHARTWELL MOLECULAR is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease.
CHARTWELL MOLECULAR's Key Drugs
CHARTWELL MOLECULAR's core commercial portfolio centers on BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
CHARTWELL MOLECULAR's Recent FDA Approvals
New NDA/BLA approvals for CHARTWELL MOLECULAR over the last two years — novel drugs only, excluding generics and label supplements.
CHARTWELL MOLECULAR's Therapeutic Areas
CHARTWELL MOLECULAR's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CHARTWELL MOLECULAR's Top Competitors
CHARTWELL MOLECULAR's closest competitors by therapeutic-area and drug-target overlap include AbbVie, WARNER CHILCOTT, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CHARTWELL MOLECULAR Pipeline Snapshot
Active clinical trials for CHARTWELL MOLECULAR across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1963-08-09
- Latest
- 2026-05-01
- Applications
- 91